核心结合因子急性髓系白血病发病机制和诊治现状被引量：1

Core-binding factor acute myeloid leukemia:an update of pathogenesis,diagnosis and novel targeted therapies

导出

摘要核心结合因子急性髓系白血病(CBF-AML)是由特定非随机性染色体易位和倒位所致,为急性髓系白血病(AML)的独立细胞遗传学亚型,一般被分为t(8;21)AML和inv(16)AML。对CBF-AML患者采取常规化疗的总体预后良好,但是成年人患者复发率可高达40%,CBF-AML复发为临床亟待解决的问题。近年研究结果表明,CBF-AML在临床表型、细胞分子遗传学和表观遗传学方面均存在较大异质性。因此,综合分析2种CBF-AML并存细胞分子遗传学异常种类和频率,对于优化CBF-AML分层诊断、预后预测,以及整合新型靶向治疗,进一步提高预后、降低复发具有重要临床意义。笔者拟就近年本领域相关研究进展阐述如下。 Core-binding factor acute myeloid leukemia(CBF-AML)is caused by specific non-random chromosome translocation or inversion,and has been categorized as an independent cytogenetic type of acute myeloid leukemia(AML).Clinically,CBF-AML is caused by t(8;21)(q22;q22),and inv(16)(p13.1;q22)or t(16;16)(p13.1;q232),and is generally divided into t(8;21)AML and inv(16)AML respectively.With conventional chemotherapy,CBF-AML is generally associated with a relatively favorable prognosis.Nevertheless,cumulative relapse rate may be up to 40%in adult patients with CBF-AML,which is the primary reason of treatment failure,and the major clinical problem to be resolved.As revealed by considerable experimental and clinical evidence,CBF-AML is quite heterogeneous in terms of clinical phenotypes,molecular cytogenetics and epigenetics.Therefore,it is of great clinical relevance to comprehensively analyze the types and frequencies of cooperating molecular cytogenetic aberrations in order to refine diagnostic stratification,to improve prognosis prediction,to select genetic-based novel targeted therapies,and to further improve the prognosis and reduce the recurrence rate of patients with CBF-AML.The current review will highlight recent experimental and clinical research findings in this particular type of de novo AML.

作者沈成奇高举郭霞代依灵饶艳琼 Shen Chengqi;Gao Ju;Guo Xia;Dai Yiling;Rao Yanqiong(Department of Pediatric Hematology,Oncology,Key Laboratory of Birth Defects and Related Diseases of Women and Children(Sichuan University),Ministry of Education,West China Second University Hospital,Sichuan University,Chengdu 610041,Sichuan Province,China)

机构地区四川大学华西第二医院儿童血液肿瘤科出生缺陷与相关妇儿疾病教育部重点实验室

出处《中华妇幼临床医学杂志（电子版）》 CAS 2018年第1期2-7,共6页 Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition)

基金四川省科技厅应用基础研究项目(2015JY0044)~~